{"entity":{"id":"nct05735080","kind":"trial","name":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","aka":[],"tldr":"A phase 1/2 trial of Fulvestrant, Abemaciclib in ovarian cancer and metastatic cancer, run by Incyclix Bio, now recruiting.","summary":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer is a phase 1/2 interventional study registered as NCT05735080 by Incyclix Bio, with 150 participants planned, started 2023-03-28 and due to reach its primary completion in 2027-07. Interventions recorded: INX-315, Fulvestrant, Abemaciclib. Conditions listed: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05735080","url":"https://clinicaltrials.gov/study/NCT05735080"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["fulvestrant","abemaciclib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05735080","phase":"1/2","setting":"A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer","sponsor":"Incyclix Bio","enrolled":150,"outcomes":[]},"route":"/trials/nct05735080/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"}]}}